Work with us

We have a custom-designed and fully optimised library for high-quality screening sets. In addition to our standard screening sets, we have more than 6000 additional fragments and near neighbours available for testing. This enables libraries to be tailored for specific classes of targets if desired. The extended collection includes analogues of primary screening compounds to enable rapid hit follow-up.

We collaborate with academic investigators from Australian and international institutes on drug discovery programs aimed to improve public health and tackle emerging diseases. Assay development and preliminary screens are provided to substantiate grant applications and we can help with grant writing. Please contact us to explore the potential of your drug target using the Monash Fragment Platform.
We provide fully assisted fragment-based drug design technologies from screening to lead development at competitive rates. Services include NMR, crystallography, SPR and medicinal chemistry. Our SPR facility can also be accessed for antibody-antigen and protein-protein interactions.
The Monash Fragment Platform has experts able to help you with your research needs. We can advise on feasibility studies, assay development, screening modalities and avenues for hit optimisation. Contact us to schedule a one-on-one discussion – consults are available to all Monash students and staff and other public and private research organisations.
The Monash Fragment Platform team provides expertise in
structural biology to support rational drug design
biophysical characterisation to quantify the affinity and kinetics of binding interactions
medicinal chemistry and chemoinformatics for the design
synthesis of elaborated fragment hits

Sidebar

External Funding Opportunities for FBDD

Therapeutic Innovation Australia
The MFP is a TIA-supported facility. We assist researchers in preparing funding applications for the TIA’s Pipeline Accelerator scheme.

Internal Funding Opportunities for FBDD

BioCurate
The BioCurate Opportunity Assessment (BOA) program runs twice a year. Application opens at the beginning of March and September annually.

Therapeutic Program Areas
The MIPS TPA Discovery Accelerator Co-funding Program will support 50% of project costs, however, special consideration may be given to award a higher percentage up to a maximum of $40,000 per grant.